The dsRNA TLR3 agonists, Ampligen (Rintatolimod) and Hiltonol, also have well described adjuvant properties [197], with Hiltonol being tested in therapeutic cancer vaccine trials (ClinicalTrials.gov Identifier: NCT04345705 and NCT02423863). This evidence concerns the gene TLR3 and cancer.